Source:		MedGen UID: 776494

     		Peginterferon alfa-2a response

			PEG-interferon alpha (PEG-IFN 2a and 2b, or
			PEG-IFN alpha), in combination with ribavirin, is
			used to treat Hepatitis C Virus (HCV) infection.
			IFNL3 (also known as IL28B) is a member of
			the type 3 IFN-alpha family, which are induced
			by viruses and inhibit HCV replication in vitro.
			Genetic variants in IFNL3 are associated with
			increased response (higher sustained virological
			response rate) to PEG-interferon alpha/ribavirin
			combination therapy and clearance of HCV. In
			2011, the protease inhibitors boceprevir and
			telaprevir were approved to treat HCV
			genotype 1 infection in many countries,
			including the United States and those in the
			European Union, and are now included in HCV
			combination therapy. IFNL3 genotype predicts
			response to this combination therapy and also
			predicts eligibility for shorter duration of
			therapy. Guidelines regarding the clinical use of
			PEG-interferon alpha containing regimens
			based on IFNL3 genotype have been published
			in Clinical Pharmacology and Therapeutics by
			the Clinical Pharmacogenetics Implementation
			Consortium (CPIC) and are available on the
			PharmGKB website

			Related Concepts
			Interferon alfa-2a product
			Peginterferon alfa-2a
			Recombinant Interferon Alfa

			30972912 Genetic variation in FCER1A
			predicts peginterferon alfa-2a-induced hepatitis
			B surface antigen clearance in East Asian
			patients with chronic hepatitis B.

     		                         Embed       Tweet       Print